bluuebunny/crossref_metadata_2025 huggingface dataset:
Inhibitory Effects of Microalgal Biofilm on Vibrio parahaemolyticus
Authors: Thi Luong Hang Pham , Thang Tran Van , Chi Truong Quynh , Trang Ngo Thi , Nhat Anh Le Van , Khoa Le Van
Published: November 2024

Microalgae are primary producers, the first trophic level in the food webs of aquatic ecosystems. Therefore, they have many potential applications in aquaculture. This study aimed to create autotrophic biofilms from microalgae strains belonging to the Nostocaceae, Protosiphonaceae, and Scenedesmaceae, isolated in Vietnam and to select a microalgal biofilm capable of inhibiting Vibrio parahaemolyticus. The microalgal biofilms were created by attaching the microalgal strains (cyanobacterium and green algae) to substrates (coconut fibre, sugarcane bagasse and cheesecloth). Additionally, the inhibitory effect of the microalgal biofilm on V. parahaemolyticus was evaluated based on the reduction proportion of V. parahaemolyticus cell numbers in an environment with the microalgal biofilm (co-culture method) compared to those in an environment without microalgal biofilm. The results showed that coconut fibre and cheesecloth had higher coverage density and biomass content of microalgae after 72 hours of biofilm formation than the sugarcane bagasse. We also found that microalgal biofilms formed by the combination of a cyanobacterial strain NK1111 with a green microalgal strain MBN1 or MHN122 reduced 76.2% - 99.8% of V. parahaemolyticus in 96 - 120 hours of co-culture. Meanwhile, microalgal biofilm formed by the strain NK1111 and a green microalgal strain MHB231 inhibited 91.8% of V. parahaemolyticus bacterium as early as 24 hours and inhibited 99.4% of this bacteria at 120 hours of co-culture. Therefore, the microalgal biofilms consisting of the strain NK1111 and the strain MHB231 on cheesecloth or coconut fibre substrate are highly appreciated for their potential application in shrimp farms in Vietnam.
Translation Procedure Applied in the Information Boards of Tegenungan Waterfall in Gianyar, Bali: A Study of Linguistics Landscape
Authors: Irwandika Gede , I Made Perdana Skolastika
Published: November 2024

This study aimed to describe translation procedures applied in the information Boards of Tegenungan waterfall in Gianyar, Bali, especially on bilingual information boards. The method used in this research was qualitative research to describe the translation procedures found on the information boards. Several theories were applied in this research: Landscape linguistics theory from Yendra and Artawa (2020), syntactic scope theory by Noortyani (2017), translation procedures by Vinay and Dalbernet (2000:84), and translation equivalence theory by Nida (2000). The analysis revealed that the information boards predominantly used literal translation, with some instances of adaptation and equivalence. Literal translation aimed to maintain the form and structure of the source language, ensuring clarity for both domestic and international visitors. However, there was room for improvement in linguistic accuracy and cultural nuances. By considering the principles of landscape linguistics and translation theory, authorities could enhance the quality of translation on the information boards. Improving the translations could lead to a more informative and engaging experience for visitors, contributing to their enjoyment and safety at Tegenungan Waterfall.
Balinese Traditional Games to Develop Children's Resilience in Early Childhood Education
Authors: Tria Ariani Nyoman Wiraadi
Published: November 2024

The Covid-19 pandemic has had a profound impact on children, with restrictions and changes in daily routines affecting their psychological well-being, including their resilience. This study examines the role of traditional Balinese games, specifically Curik-curik, in fostering children's resilience. Using the case study method, we analyze the aspects that shape children's resilience during the game of Curik-curik. The results reveal that this traditional game provides a natural and effective means for children to communicate their feelings, reducing their worries and anxieties. Moreover, participating in Curik-curik enables children to develop self-control, emotional management, and problem-solving skills, preparing them to face real-life changes and obstacles. By engaging in traditional Balinese games, children can cultivate resilience and be better equipped to tackle new challenges in their growth journey.
SUMBER KEJAHATAN DAN PENDERITAAN DALAM WACANA FILSAFAT AGAMA DAN KRITIK ATAS ARGUMEN TEODISE PERSPEKTIF IMMANUEL KANT
Authors: Siswadi Gede Agus , Syamsuddin M. Mukhtasar , Puspadewi I Dewa Ayu
Published: November 2024

Penelitian ini membahas sumber kejahatan dan penderitaan dalam konteks wacana filsafat agama serta kritik terhadap argumen teodise dari perspektif Immanuel Kant. Dalam filsafat agama, problematika kejahatan dan penderitaan menimbulkan tantangan terhadap keberadaan Tuhan yang Maha Baik, Maha Kuasa, dan Maha Tahu. Tradisi teodise berupaya mempertahankan koherensi atribut-atribut ilahi dengan keberadaan kejahatan, tetapi sering kali menghadapi berbagai kritik. Penelitian ini memfokuskan pada pendekatan Kant persoalan ini yang menolak konsep teodise konvensional dan mengalihkan perdebatan dari pembenaran Tuhan kepada dimensi moralitas manusia. Melalui metode penelitian kualitatif dengan pendekatan hermeneutik filosofis, maka hasil dalam penelitian ini menunjukkan bahwa Immanuel Kant menolak upaya tradisional untuk membenarkan Tuhan di hadapan kejahatan dan penderitaan, dengan alasan bahwa argumen teodise gagal secara moral dan epistemologis. Sebaliknya, Kant mengusulkan bahwa manusia seharusnya mengarahkan perhatiannya pada kewajiban moral dan tanggung jawab etis untuk mengatasi penderitaan dan kejahatan. Kant berpendapat bahwa kapasitas manusia untuk memilih antara baik dan buruk menjadi dasar bagi pemahaman tentang kejahatan, dan bahwa kejahatan merupakan konsekuensi dari penyalahgunaan kebebasan moral manusia. Selain itu, Kant menegaskan bahwa kepercayaan pada Tuhan harus didasarkan pada moralitas praktis daripada bukti spekulatif yang sering digunakan dalam argumen teodise. Oleh karenanya Kant menggeser fokus dari pembelaan teoretis tentang kejahatan ke pendekatan praktis dan etis, yang mendorong manusia untuk memperbaiki kondisi dunia melalui tindakan moral.
Más allá del orden de la naturaleza. Reflexiones desde la historia de las ciencias
Authors: Duque Martínez Luz Marina
Published: November 2024

La acepción de determinismo que se estudia en este libro está relacionada con la revolución científica del siglo XVII y con la propuesta de la mecánica clásica de Newton. En ese entonces se confió en que se habían logrado expresar las regularidades de la naturaleza como leyes que gobernaban el mundo natural sin distinguir lo que pasaba en los cielos de lo que ocurría en la Tierra. La capacidad de predecir el comportamiento de la naturaleza es la característica distintiva de esta concepción determinista asociada a las leyes. Fue un gran logro y permitió que el conocimiento científico se desarrollara hasta finales del siglo XIX a un ritmo no conocido previamente. Para entonces, científicos de diferentes campos de investigación descubrieron que algunos fenómenos de la naturaleza presentaban comportamiento aleatorio y que la anhelada predicción se escapaba de las manos, siendo remplazada por el cálculo de probabilidades.
PENGHANCURAN WARISAN BUDAYA DI TIMBUKTU OLEH ANSAR DINE DI TAHUN 2012: PELANGGARAN TERHADAP KONVENSI DEN HAAG 1954?
Authors: Pashya Habib , Faradila Muslihah , Nurfitriyani Resti , Istiqomatunnisa
Published: November 2024

The armed conflict in Mali since 2012 has had a significant impact on the destruction of various cultural sites, particularly in Timbuktu. The research method used in this research is a literature study by reviewing various relevant literatures on the case study, while using a normative-juridical approach through analysis of the articles of the Hague Convention and international judicial decisions through the articles contained in the Rome Statute. This is because this conflict has resulted in significant violations of the 1954 Hague Convention, which regulates the Protection of Cultural Property in the Event of Armed Conflict as stated in Article 2 regarding the importance of protecting cultural property in conflict areas. Moreover, there have been violations of the Rome Statute governing the jurisdiction of the International Criminal Court (ICC). In addition, this conflict has violated the principles of distinction and precaution as it has resulted in the destruction of civilian objects such as places of worship categorized as cultural heritage. The purpose of this study is to highlight the importance of implementing international law in protecting the cultural heritage owned by every nation. Furthermore, this research emphasizes the importance of stronger international cooperation to protect cultural heritage, especially in areas prone to armed conflict. It also emphasizes the importance of taking firm action against violators of international humanitarian law such as the ICC trial of Al-Mahdi from Ansar Dine for the destruction of cultural heritage in Timbuktu.
PENGARUH KEBIJAKAN LUAR NEGERI TERHADAP HUKUM PIDANA INTERNASIONAL
Authors: Ferdiansyah Ferdy , Pribadi Riky
Published: November 2024

The application of international criminal law in Africa is greatly influenced by the foreign policies of international actors and African countries themselves. The foreign policies of international actors, such as Western countries and multilateral organizations, often determine support for or rejection of institutions such as the International Criminal Court (ICC). This international support, whether diplomatic pressure or financial assistance, strengthens the role of international legal institutions in the prosecution of serious crimes in Africa. However, this relationship also gives rise to political tensions, where several African countries see this intervention as a form of neo-colonialism and ignore their national sovereignty. On the other hand, the foreign policies of African countries show complex dynamics. Some countries, such as Botswana, fully support the ICC as a means of ensuring accountability, while others, such as Sudan and Kenya, reject international intervention, especially in cases involving their political leaders. The relationship between African states and the international community in the process of implementing international criminal law reflects the efforts made to balance the need for international justice with the protection of state sovereignty. In this context, the development of regional alternatives such as the African Criminal Court is also a response to tensions with the Western-dominated international legal system.
Women Empowerment through Cooperatives Savings & Loan Cooperatives
Authors: Grace Fransisca Christine , Radyati Maria R. Nindita , Utha Maria
Published: November 2024

The role of social capital in women's empowerment through cooperatives has a multiplier effect that contributes significantly to the improvement of the household economy and the economic growth of the community. The object of this research is the Mawar Kusuma Savings and Loan Cooperative (Credit Union) and the Tanjung Sari Women's Cooperative. The total resource persons were 89 people with the technique of determining the sources using purposive techniques. Data was collected using in-depth interviews and questionnaires. This type of research is a mixed method that is qualitative-quantitative. The method of analysis is content analysis. The results of the study indicate that both cooperatives have played a role in developing social and economic empowerment for their members. Contributing to women's empowerment towards sustainable development goals through cooperatives that continue to improve governance that strengthens women's ability to access markets, generate income, and reduce poverty levels. Thus, cooperatives enable many women to be more useful and bring a positive multiplier effect for families and society.
Pengaruh Pemberian Jus Tomat Terhadap Penurunan Tekanan Darah Pada Penderita Hipertensi Literature Review
Authors: Aisah Siti , Lismayanti Lilis
Published: November 2024

Pendahuluan Hipertensi, atau tekanan darah tinggi, merupakan masalah kesehatan yang serius dan dapat meningkatkan risiko penyakit kardiovaskular. Banyak penelitian telah dilakukan untuk mencari solusi alami dalam menangani hipertensi, dan salah satu bahan alami yang menarik perhatian adalah jus tomat. Hipertensi merupakan masalah yang cukup besar di seluruh Indonesia, dinyatakan dengan jumlah kasus hipertensi di Indonesia sebesar 63.309.620 orang. Sedangkan angka kematian di Indonesia akibat hipertensi sebesar 427.218 kematian Tujuan literature Review ini untuk mengetahui pengaruh jus tomat terhadap penurunan tekanan darah pada penderita hipertensi. Metode Penelitian : penelitian ini menggunakan metode Literature Review dengan menggunakan google scholar antara tahun 2018-2023. Pembahasan : jus tomat mengandung senyawa bioaktif seperti likopen, beta-karoten, vitamin C, dan potassium, yang memiliki potensi untuk menurunkan tekanan darah. Hasil : dari literature review ini bahwa terapi komplementer terhadap jus tomat. Menunjukan hasil yang signifikan terhadap penurunan tekanan darah. Kesimpulan : konsumsi jus tomat segar efektif untuk membantu penderita hipertensi dalam pengendalian tekanan darah sistolik dan diastolik. Saran : Diharapakan dapat dijadikan masukan sebagai penyusun standar operational prosedur (SOP) untuk penatalaksanaan tindakan keperawatan pada penderita hipertensi.
Desenvolvimento de software para autocuidado nutricional de pacientes oncológicos
Authors: Ferreira Mylenne Cardim , Pinheiro Dirce Nascimento
Published: November 2024

Objetivo: desenvolver um software em formato de aplicativo para dispositivos móveis com enfoque no autocuidado nutricional de pacientes oncológicos. Métodos: Trata-se de um estudo descritivo, do tipo desenvolvimento metodológico, constituído por três etapas (revisão de literatura, criação e desenvolvimento do protótipo e a validação do protótipo por juízes especialistas). Para a análise da avaliação do aplicativo, foi realizado o cálculo do Índice de Validade de Conteúdo (IVC). O projeto foi submetido ao Comitê de Ética do Instituto de Ciências na Saúde (ICS) da Universidade Federal do Pará (UFPA). Resultados: A ferramenta aborda sete tópicos, como avaliação antropométrica, percentual de perda de peso, cálculo da necessidade hídrica diária, orientações sobre alimentação saudável, estratégias nutricionais para quimiotoxicidades gastrointestinais, frutas da estação e receitas saudáveis. A análise dos juízes demonstrou que a tecnologia educativa proposta possui validade para ser utilizada com o público alvo (IVC maior que 0,8). Conclusão: Desta forma, espera-se que o produto elaborado nesta pesquisa, estimule que os pacientes e seus cuidadores exerçam a autonomia do cuidado, promovendo uma melhor resposta ao tratamento e prognostico clínico.
Análise da deficiência de vitamina B12 em pacientes pós cirurgia bariátrica em um hospital privado da região amazônica
Authors: Gomes Jéssica Aleixo , Souza Bruna Fernanda Moraes de , Yasojima Edson Yuzur , Valente Tárik Olivar de Nunes
Published: November 2024

Objetivo: Analisar e comparar, por meio do perfil laboratorial, a vitamina B12 de pacientes submetidos à cirurgia bariátrica pela técnica "Bypass gástrico" durante o período entre 2012 a 2022. Métodos: O estudo observacional e retrospectivo analisou dados de 102 pacientes do banco de dados Bariatric System®, usado pela equipe de cirurgia bariátrica de um hospital no estado do Pará. Avaliou-se características demográficas e níveis de vitamina B12 em período pré e pós-operatórios (1º, 5º e 10º ano). Os dados foram analisados com Python 3.8 e Microsoft Excel® 365. Resultados: A amostra, possui maior incidência de pessoas encontradas nas faixas etárias de 18-25 anos e 26-35 anos, com 24,51% cada, e tem predomínio do público feminino (56,86%). A deficiência de vitamina B12 é mais prevalente no período pré-operatório (79,4%) e no 1° ano pós cirúrgico (62,7%), tendo queda no 5º ano (21,6%) e 10º ano (14,7%). Observa-se maior incidência de deficiência em mulheres, particularmente no 1º e no 10º ano pós-operatórios. Conclusão: Há déficit de vitamina B12 nos pacientes submetidos ao BGYR em todo período analisado, fazendo-se necessário o acompanhamento laboratorial da vitamina e o suporte nutricional adequado por toda vida.
Eosinophil-rich Linear IgA Bullous Dermatosis: A Case Report of a Rare Entity
Authors: Odango Celter , Im Grace , Wills Abigail , Gradecki Sarah , Flowers Richard
Published: November 2024

Linear IgA bullous dermatosis (LABD) is an uncommon autoimmune bullous disease characterized by a subepidermal neutrophilic infiltrate. It classically presents as widespread tense vesicles in an annular pattern and is defined by the presence of linear deposition of IgA at the dermal-epidermal junction. Eosinophil-rich LABD has been rarely reported in the literature, including in association with COVID-19 booster vaccination, parvovirus B19 infection, hematologic malignancies, and drug-induced LABD. The varied clinical and histopathologic findings often make it difficult to differentiate LABD from other blistering diseases such as bullous pemphigoid and dermatitis herpetiformis. For this reason, immunofluorescence and serologic testing are critical for identifying the underlying diagnosis.
Palmoplantar Psoriasis Treatment with Topical Roflumilast 0.3%
Authors: Ruiz Dasilva Diego
Published: November 2024

Palmoplantar psoriasis is a manifestation of psoriasis that includes pustules, scales, and erythematous hyperkeratotic plaques on the palms of the hands and the soles of the feet. Despite being limited to these regions, palmoplantar psoriasis is difficult to treat and imposes a greater level of quality-of-life burden compared to plaque psoriasis. We describe a case of palmoplantar psoriasis refractory topical corticosteroid and dupilumab that was successfully treated with topical roflumilast 0.3% once daily.
Successful Treatment of Perioral Dermatitis with Upadacitinib
Authors: Patel Anya , Lau William , Lebwohl Mark
Published: November 2024

Perioral dermatitis (POD) is a benign, chronic inflammatory skin condition characterized by small papules, pustules, and erythematous scaly patches around the perioral region. Treatment is not reliably effective, and the condition can be prolonged. We herein report a case of the successful treatment of perioral dermatitis (POD) using upadacitinib. A 45-year-old female with a history of rosacea, presented to the clinic with a 2-3-year history of severely pruritic erythematous papules around the chin and mouth, consistent with POD. Our study demonstrates that Janus kinase inhibitors are a promising therapeutic modality for this condition.
Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, with Rapid Improvement Following IL-17A/IL-17F Blockade by Bimekizumab
Authors: Orloff Jeremy , Domzalski Grayson , Amara Shivkar , Lebwohl Mark
Published: November 2024

Introduction: Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder which can severely affect patient quality of life. While there are no FDA-approved therapies for PRP, methotrexate and acitretin are often used as first line treatments.  Recent analyses have implicated dysregulation of the IL23/IL17 axis in PRP pathogenesis and the use of biologics for severe cases have been reported in the literature.
Case Report: We report the case of a male in his thirties who presented with PRP refractory to a second course of secukinumab. Physical exam revealed diffuse salmon-colored hyperkeratotic patches coalescing to cover his entire body (BSA >95%). The patient was started on combination therapy with acitretin and bimekizumab. The patient recovered rapidly, with near total resolution of his skin findings four weeks after beginning treatment.
Discussion: Unlike earlier biologics targeting IL-17, bimekizumab has activity on IL-17F in addition to IL-17AF and IL-17A. The efficacy of bimekizumab in this case may signify an important role for IL-17F in PRP pathogenesis. Bimekizumab may offer improved efficacy for the treatment of pityriasis rubra pilaris (PRP) in patients who do not respond to other therapies.
Multiple Injection Site Reactions after Treatment with Different Biologics for Psoriasis and Psoriatic Arthritis
Authors: Domzalski Grayson , Lau William , Barzi Rebecca , Miller Rachel , Lebwohl Mark
Published: November 2024

Psoriasis (PsO) is an autoimmune disease characterized by erythematous, pruritic, and scaly plaques that can be distributed throughout the body. The development of biologic treatments targeting an array of molecular pathways, including tumor necrosis factor-ɑ  or interleukins (IL) 12, 23, 17A, and 17F, has advanced treatment options for these patients. In this article, we report a unique case of a 35-year-old female with 11-year history of PsO and a new onset of guttate PsO following an episode of streptococcal pharyngitis. She was subsequently treated with guselkumab, bimzekizumab, and ixekizumab, developing injection site reactions to each biologic. The patient was suspected to be allergic to polysorbate-80 (PS-80), an aqueous medium to stabilize biologics before administration. Notably, the patient had a negative response to PS-80 on allergy testing, and it remains unclear why the patient experienced ISR with certain medications and not others. Further research is needed to characterize ISR across the different biologics, particularly newer medications being utilized in clinical settings.
The Treatment of Lichen Sclerosus with Topical Roflumilast 0.3% Case Study
Authors: Domingues Erik
Published: November 2024

Lichen Sclerosus is a chronic inflammatory skin disease predominantly affecting post-menopausal women. Currently, the first line treatment approach for lichen sclerosus is ultra potent topical corticosteroids for 12 weeks. A treatment challenge to this approach is the risk of steroid atrophy due to the use of potent topical steroids on the genital skin. We describe reduction of erythema and symptomatic improvement following treatment with topical roflumilast 0.3% once daily in a patient with lichen sclerosus who refused topical corticosteroids.
A Systematic Review of the Association of Elastosis Perforans Serpiginosa and Congenital Disorders
Authors: Heckman Carolyn , Flatley Elizabeth , Janodia Rucha
Published: November 2024

Background: Elastosis perforans serpiginosa (EPS) is a skin condition marked by transepidermal elimination of abnormal elastic fibers, with a classical presentation of papules or plaques arranged in serpiginous, annular, or arcuate patterns on the neck, face, arms, or other flexural regions. A previous review of the literature reported that approximately 1/4 of EPS cases are associated with congenital disorders, including Down syndrome, Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum. To the knowledge of these authors, no review examining the association of EPS and congenital disorders has been performed since 1968.
Objective: The primary objective of this paper is to perform an updated review of the literature focused on the associations between EPS and congenital disorders.
Methods: We searched electronic databases (Medline, Web of Science, PubMed) for literature pertaining to EPS and Down syndrome, Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum.
Results: Evidence for the association of EPS and congenital disorders is 57 cases from 48 published papers.
Conclusions: Our results suggest an association between EPS and congenital disorders. However, current evidence is limited to case reports, underscoring the need for future research investigating the relationship between EPS and congenital disorders.
Utilizing Upadacitinib for the Management of Hailey-Hailey Disease
Authors: Fung Hayden , Lau William , Lebwohl Mark
Published: November 2024

Hailey-Hailey Disease (HHD) is a rare disease associated with mutation of the ATP2C1 gene characterized by skin blistering and erosion. Here, we report a case of a patient with HHD who significantly improved after treatment with upadacitinib. A 55-year-old male with biopsy-confirmed Hailey-Hailey disease presented with a 20-year history of ill-defined, brightly erythematous, painful patches initially on the neck and subsequently involving the penile shaft. Following treatment with 30mg of upadacitinib, the patients neck ulcers gradually re-epithelized. This case adds to the growing body of literature supporting the use of Janus kinase inhibitors as a therapeutic modality for this condition.
Carpal Tunnel Corticosteroid Injection Treatment of Nail Lichen Planus
Authors: Lee-Foltz Miranda , Shah Payal , Aaron Denise
Published: November 2024

Treatment for nail lichen planus (NLP) typically involves the use of intralesional or systemic corticosteroids. However, both modalities have distinct considerations. Systemic options are typically reserved for severe cases due to potential adverse effects while intralesional injections are limited due to patient discomfort. Here we present a case in which a corticosteroid injection for carpal tunnel syndrome led to incidental bilateral improvement in a patient’s nail lichen planus. Carpal tunnel injection may be an alternative to more traditional treatments and is a potential area for further research.
How Automation in Electronic Medical Records Can Lead to Errors in Dermatology
Authors: Nguyen Kaycee , Cockerell Clay
Published: November 2024

The integration of electronic health records has revolutionized healthcare by facilitating communication among providers, but it has also introduced significant challenges. In dermatology, a particular issue arises with the use of electronic medical record (EMR) systems that employ auto-populated fields on digital pathology requisition forms (RFs) for skin biopsies. These systems allow for the rapid selection of pre-set descriptions and differential diagnoses, which, while timesaving, frequently lead to diagnostic inaccuracies and potentially detrimental impacts on patient care.
Dermatopathologists often receive biopsy specimens with RFs that list multiple provisional diagnoses based on generic, EMR-generated descriptions, which may not accurately represent the patient’s condition. This practice hampers the ability of dermatopathologists to perform effective clinicopathologic correlation, crucial for accurate diagnosis. We highlight that the convenience of EMR systems can discourage clinicians from recording detailed, accurate clinical observations. Consequently, this lack of detailed documentation prevents dermatopathologists from making informed diagnoses by correlating histologic features with clinical appearances. The current practice of using EMRs without consideration for their clinical relevance not only wastes healthcare resources but also poses a significant medico-legal risk. Therefore, refining EMR practices and integrating more comprehensive clinical data will ensure greater accuracy in dermatological diagnoses.
Effects of Mineral and Almond Oil Administration on Transepidermal Water Loss and Skin Acidity in Chronic Renal Failure Patients Undergoing Hemodialysis
Authors: Oktaviani Trya , Ellistasari Endra Yustin , Anandita Benedikta Lauda
Published: November 2024

Introduction: Patients undergoing hemodialysis experience decreased moisture content in the dermis due to fluid transfer during the dialysis process, causing xerosis, pruritus, and damage to the skin barrier. Almond oil and mineral oil are well-known moisturizers used in skin care products.
Objectives: To compare the effect of almond oil with mineral oil on transepidermal water loss (TEWL) and skin acidity in hemodialyzed chronic renal failure (CRF) patients.
Methods: An experimental study was conducted on patients with chronic renal failure (CRF) undergoing hemodialysis at Dr. Moewardi Hospital in Indonesia. The study involved applying mineral and almond oils twice daily on the right and left forearms for four weeks. We measured TEWL and pH levels before and after the treatment.
Results: There is a significant difference in TEWL between before and after mineral oil application (p=0.036), but not in the almond oil arm (p=0.394). Subsequently, the change of TEWL value significantly differed between mineral oil and almond oil (p=0.043). However, the effects of mineral oil and almond oil on pH were insignificant (p=0.574 and 0.268, respectively).
Conclusion: After undergoing hemodialysis, CRF patients experienced a statistically significant reduction in transepidermal water loss (TEWL) when using mineral oil compared to both baseline and almond oil.
Publication Outcomes of Abstracts Presented at the 2020 Society for Investigative Dermatology Annual Meeting
Authors: Brown Madeline , Mammen Priscilla , Dunbar Dakarai , Zhou Albert , Feng Hao
Published: November 2024

The Society for Investigative Dermatology (SID) was created to promote the advancement of skin biology research. The organization hosts a conference annually that allows for the dissemination of basic science knowledge to advance dermatology research to new heights. Our study investigates the publication status of research abstracts presented at SID to determine if publication rates were similar to those of other widely attended conferences in dermatology. We performed a literature search for each abstract presented at the conference in 2020 and found that only 27.6% of abstracts make it to publication. Due to various reasons outlined in this article, publication rates of SID projects are lower than many other dermatology conferences attended. Therefore, conference participants should be aware of how study designs and research topics can influence publication outcomes.
Investigating the Impact of Financial Sponsorship in Dermatology Research
Authors: Shaikh Umayr , Ajmani Ayushya , Makaj David , Shah Payal
Published: November 2024

Introduction: Financial sponsorship plays a crucial role in advancing dermatologic research, yet its impact on research quality and visibility is not well-defined. This study aims to evaluate the association between financial sponsorship and the quality of evidence, publication impact, and research collaboration in dermatology.
Methods: We analyzed 1,380 dermatology articles published from October 2013 to October 2023 in three leading journals. Data collection was conducted using REDCap. We assessed the proportion of sponsored studies and their impact in terms of citation frequency, author count, and journal impact factors. Statistical analyses were performed using t-tests, chi-squared tests, and regression analysis in STATA VSN 16.1.
Results: Sponsored articles comprised 48.2% of the total, with the National Institutes of Health (NIH) being the predominant funder. These articles showed significantly higher citation rates and more authors per article compared to non-sponsored ones. The mean journal impact factor was also higher for sponsored studies. Furthermore, sponsored studies were more likely to employ prospective study designs, indicative of higher evidence quality.
Discussion: Financial sponsorship significantly enhances the visibility and quality of evidence in dermatologic research. The findings underscore the need for increased advocacy for funding, particularly in clinical research within dermatology, to foster greater research collaborations and more impactful scientific discoveries.
A Case of Cutaneous Squamous Cell Carcinoma Treated with Neoadjuvant Cemiplimab
Authors: Hasan Iraj , Garland-Kledzik Mary
Published: November 2024

We present a case describing the successful treatment of a 68-year-old male with high-risk cutaneous squamous cell carcinoma (cSCC) using neoadjuvant cemiplimab. The patient presented with a rapidly growing papule on the left hand, which was initially treated with wide local excision and subsequently developed axillary lymphadenopathy. After radiation therapy led to complications, the patient received four cycles of cemiplimab, resulting in significant tumor necrosis and minimal residual disease. This case underscores the potential of cemiplimab as a neoadjuvant therapy for cSCC, offering an effective treatment with fewer adverse effects compared to traditional therapies. The report highlights the importance of a multidisciplinary approach in optimizing outcomes for patients with advanced cSCC.
Recalcitrant Scalp Psoriasis Successfully Treated with Once-Daily Roflumilast Cream 0.3%
Authors: DOMINGUES ERIK
Published: November 2024

Scalp psoriasis is a chronic, immune-mediated skin disease with varying phenotypes and is estimated to affect up to 80% of individuals suffering from psoriasis [1].  The physical symptoms, along with social and emotional impacts of scalp psoriasis can significantly reduce quality of life, necessitating long-term treatment for most patients [3]. Numerous topical and systemic treatments are available for scalp psoriasis, yet the condition remains challenging to manage, underscoring a persistent unmet need for safe and effective therapies [2].   Treatment of the scalp and other hair bearing areas is challenging and can affect the ability to apply topical products and hinder their efficacy [2, 3].  Roflumilast cream 0.3% is a highly selective, non-steroidal and potent topical phosphodiesterase 4 (PDE4) inhibitor approved in 2022 by the FDA for the treatment of psoriasis, including intertriginous disease; in 2023 as a foam for the treatment of seborrheic dermatitis and in 2024, roflumilast cream 0.15% was approved for the treatment of atopic dermatitis.  Roflumilast has demonstrated a higher affinity for binding to PDE4 relative to other approved PDE4 inhibitors resulting in greater potency [4, 5]. The results of a phase 3 study investigating roflumilast foam 0.3% in patients with scalp and body psoriasis showed that once daily treatment produced significant clearance of affected areas, rapid improvement in pruritus, and was well-tolerated [6].  Here we report a case involving a 28-year-old female with recalcitrant scalp psoriasis following 10 years of unsuccessful treatment with topical products. Due to the severity of adverse effects experienced with prior therapies, the patient was reluctant to initiate systemic therapy and a trial of once daily topical roflumilast cream 0.3% was initiated. The patient demonstrated rapid improvement after 3 days and clearance of the scalp lesion following daily application for 5 days without any reported adverse effects. Lesions on the patient’s torso also cleared.  Upon clearance of lesions, the patient discontinued application of roflumilast cream, and lesions remained clear for several weeks and applies only as needed with any recurrence.  Our patient’s case demonstrates the significant potential of roflumilast cream 0.3% in addressing the inflammatory etiology of scalp psoriasis.
Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Authors: Armstrong April W. , Lebwohl Mark , Warren Richard B. , Sofen Howard , Morita Akimichi , Imafuku Shinichi , Ohtsuki Mamitaro , Spelman Lynda , Passeron Thierry , Papp Kim A. , Colombo Matthew J. , Vaile John , Vritzali Eleni , Hoyt Kim , Daamen Carolin , Banerjee Subhashis , Strober Bruce , Thaçi Diamant , Blauvelt Andrew
Published: November 2024

Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was superior to placebo and apremilast in the global, 52-week, phase 3 POETYK PSO-1 and PSO-2 parent trials in moderate to severe plaque psoriasis. Upon completion, patients could enroll in the ongoing POETYK long-term extension (LTE) trial. Here, deucravacitinib safety/efficacy are reported through 4 years.
Methods: PSO-1/PSO-2 randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At Week 52, patients enrolled in the LTE received open-label deucravacitinib. Safety was evaluated in patients receiving ≥1 deucravacitinib dose. Exposure-adjusted incidence rate (EAIR) per 100 person-years (PY) was used to assess adverse events (AEs). Efficacy outcomes included PASI 75, PASI 90, and sPGA 0/1 and were analyzed using mNRI in LTE patients receiving continuous deucravacitinib from Day 1 of the parent trials.
Results: 1519 patients received ≥1 deucravacitinib dose; cumulative exposure was 4392.8 PY. EAIRs/100 PY were decreased/comparable from the 1-year to 4-year cumulative period, respectively, for AEs (229.2, 131.7), serious AEs (5.7, 5.0), deaths (0.2, 0.3), discontinuation due to AEs (4.4, 2.2), herpes zoster (0.8, 0.6), malignancies (1.0, 0.9), major adverse cardiovascular events (0.3, 0.3), and venous thromboembolism (0.2, 0.1). Clinical response rates with continuous deucravacitinib (n=513) were maintained from Year 3 (PASI 75, 73.8% [95% CI, 69.6-78.0]; PASI 90, 49.0% [44.4-53.7]; sPGA 0/1, 55.2% [50.5-59.9]) to Year 4 (PASI 75, 71.7% [67.0-76.3]; PASI 90, 47.5% [42.6-52.4]; sPGA 0/1, 57.2% [52.1-62.2]) by mNRI.
Conclusion: Deucravacitinib demonstrated a safety profile through 4 years consistent with 3 years with no emergence of new or long-term safety signals. Efficacy was maintained through 4 years in patients receiving continuous deucravacitinib from Day 1 in PSO-1/PSO-2.
Provider Burden Associated With Apremilast Adverse Events
Authors: Schmidt Lana , Wu Ying , Patel Vardhaman , Gentile Danielle , Liassou Djibril , Sharpe Jason , Omary Courtney , Ahlquist Monica , Feinberg Bruce
Published: November 2024

Introduction: In December 2021, the US Food and Drug Administration (FDA) expanded its initial approval for apremilast to include moderate and severe cases of psoriasis. However, real-world epidemiology data regarding the use of apremilast, the influence of adverse events (AEs), and the burden of AEs on managing physicians, has been lacking. This retrospective, observational, multisite study aimed to describe real-world patient characteristics, AEs (including diarrhea, nausea, and headache), and healthcare provider-level burden associated with the psoriasis treatment apremilast in the US.
Methods: Dermatologists abstracted medical record data for adults treated with apremilast on or after January 1, 2018, who had ≥3 months of data available. Dermatologist and patient characteristics, including demographics and clinical characteristics, AEs, and provider burden in managing AEs were summarized using descriptive statistics.
Results: Forty-seven dermatologists nationwide responded to a survey and conducted a chart review of 308 patients. Dermatologists practiced in various US geographic regions. The most common practice setting was in a private community with 2 to 5 physicians (34.0%). Most patients were White (74.4%), non-Hispanic (86.0%), and male (55.2%). The mean age at diagnosis was 43.6 years (SD, 16.8 years). AEs occurred in 29.2% of patients, with the most common being diarrhea (16.2%), followed by nausea (13.6%) and headache (4.9%). Diarrhea mostly occurred ≤30 days into treatment (87.2%) and resulted in 1 additional office visit (39.5%) and 3 phone calls per patient to their providers (34.9%). Nausea mostly occurred within 30 days (70.2%) and resulted in 1 additional visit (29.7%) and 1 phone call per patient (35.1%). The burdens of managing both diarrhea and nausea were similar, although diarrhea resulted in more phone calls to the healthcare provider.
Conclusion: Diarrhea and nausea were common and resulted in an additional time and resource burden on dermatologists and their staff. Future research on the AE burden on providers and patients related to apremilast is needed.
Deucravacitinib in Moderate to Severe Plaque Psoriasis: Comorbidities and Use of Prior and Concomitant Medication in Patients Enrolled in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Authors: Merola Joseph F. , Gottlieb Alice B. , Mehta Nehal N. , Colombo Matthew J. , Elias Monica , De Leonardis Francesco , Jou Ying-Ming , Korman Neil J.
Published: November 2024

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was superior to placebo and apremilast in two global, phase 3 trials, POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751), in moderate to severe plaque psoriasis. Here, we evaluate the comorbidities present at baseline and use of prior and concomitant medications in the pooled POETYK PSO-1 and PSO-2 trial populations to more comprehensively describe the medical history of individuals who participated in the deucravacitinib phase 3 trials.
Methods: In POETYK PSO-1 and PSO-2, adults with moderate to severe plaque psoriasis were randomized 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. The rates of baseline comorbidities and medications received before and concomitantly with deucravacitinib in the pooled POETYK PSO trials were assessed. Medication classes evaluated included antidiabetic, antihypertensive and cardiovascular, lipid-reducing, anti-anxiety/depression, and oral contraceptive therapies.
Results: Baseline patient demographics were similar across treatment arms. Metabolism and nutrition disorders were reported most often in each treatment arm (placebo, 42.7%; deucravacitinib, 39.2%; apremilast, 38.4%), followed by vascular disorders (33.7%, 34.9%, and 31.8%, respectively). Hypertension was the most common baseline medical condition (placebo, 30.3%, deucravacitinib, 32.8%, and apremilast, 29.1%), with obesity, hyperlipidemia, type 2 diabetes mellitus, and seasonal allergies each reported in 10% to 12% of patients in at least one treatment arm. Antihypertensive and cardiovascular agents, lipid-reducing agents, and antidiabetic agents were the most commonly reported medications.
Conclusion: The phase 3 POETYK PSO trials enrolled adults with moderate to severe plaque psoriasis with a range of comorbidities consistent with the real-world population of patients with psoriasis. Medication classes used by patients were consistent with the comorbidities reported at baseline in both trials.
Efficacy of Deucravacitinib in Plaque Psoriasis Across a Range of Body Surface Area Involvement: Post hoc Analysis of the Randomized, Double-Blinded, Placebo-Controlled, Phase 3b/4 PSORIATYK SCALP Trial
Authors: Blauvelt Andrew , Thaçi Diamant , Pariser David M. , Napoli Andrew , Balagula Eugene , Cheng Chun-Yen , Dyme Rachel , Stein Gold Linda , Lebwohl Mark
Published: November 2024

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Scalp involvement affects approximately 80% of patients with plaque psoriasis. PSORIATYK SCALP (NCT05478499) is an ongoing, 52-week, multicenter, phase 3b/4 trial evaluating deucravacitinib in patients with moderate to severe scalp psoriasis, including those with a range of total body surface area (BSA) involvement (≥3%). These patients are candidates for systemic therapy, according to the AAD/NPF and IPC treatment guidelines. This post hoc analysis assessed efficacy in overall body psoriasis.
Methods: Adults (age ≥18 years) with moderate to severe scalp psoriasis (scalp-specific Physician Global Assessment [PGA] ≥3, scalp surface area involvement ≥20%, and Psoriasis Scalp Severity Index ≥12 at baseline) and BSA involvement ≥3% were eligible for inclusion. Patients were randomized 1:2 to oral placebo (n=51) or deucravacitinib 6 mg once daily (n=103) through Week 16. Stratification factors included prior biologic use and body weight. Outcomes at Week 16 included static PGA score of 0 (clear) or 1 (almost clear) (sPGA 0/1), change from baseline in Psoriasis Area and Severity Index (PASI), and change from baseline in whole-body itch numeric rating scale (NRS). Nonresponder imputation (binary outcomes) and modified baseline observation carried forward (continuous outcomes) were used for patients with missing data. All P values are nominal.
Results: Baseline characteristics were similar between groups (deucravacitinib: mean [SD], BSA 10.5% [9.6%], PASI 10.2 [6.7], whole-body itch NRS 5.8 [2.8]; placebo: mean [SD], BSA 10.0% [8.1%], PASI 9.4 [5.6], whole-body itch NRS 5.8 [2.4]). Baseline total BSA involvement was 3%-10% in most patients (deucravacitinib, 68.0%; placebo, 74.5%). At Week 16, a significantly higher proportion of patients receiving deucravacitinib versus placebo achieved sPGA 0/1 (47.6% [95% CI, 37.6%-57.6%] vs 3.9% [0.5%-13.5%], respectively; P<0.0001). Similarly, patients treated with deucravacitinib achieved greater decreases in adjusted mean change from baseline in PASI (−6.4 [95% CI, −7.3 to −5.5] vs −1.3 [−2.6 to −0.1]; P<0.0001) and whole-body itch NRS (−2.9 [−3.4 to −2.4] vs −0.4 [−1.1 to 0.3]; P<0.0001).
Conclusion: In the phase 3b/4 PSORIATYK SCALP trial, deucravacitinib was efficacious in improving overall psoriasis. Efficacy was consistent with the results observed in the phase 3 POETYK PSO-1/PSO-2 trials, despite including patients with less extensive total BSA involvement.
Bimekizumab Efficacy and Safety in Patients With Psoriatic Arthritis Who Had Skin and Nail Psoriasis at Baseline: Up to 2-year Results From Two Phase 3 Studies
Authors: Thaçi Diamant , Asahina Akihiko , Boehncke Wolf Henning , Gottlieb Alice , Lebwohl Mark , Warren Richard , Ink Barbara , Bajracharya Rajan , Coarse Jason , Merola Joseph
Published: November 2024

Introduction: Bimekizumab (BKZ), a humanized anti-IL17F anti-IL17A antibody has demonstrated efficacy and tolerability to 1 year in patients with psoriatic arthritis (PsA) and psoriasis.1 Nail psoriasis is associated with increased PsA risk, more severe disease and decreased quality of life, in patients with psoriasis.2,3
Here, efficacy and safety of BKZ treatment are reported to 2 years in patients with PsA, skin involvement and nail psoriasis in two phase 3 trials.
Methods: BE OPTIMAL (NCT03895203; bDMARD-naïve) and BE COMPLETE (NCT03896581; TNFi‑IR) assessed subcutaneous BKZ 160 mg Q4W in patients with PsA. Placebo (PBO) patients switched to BKZ (PBO/BKZ) at Wk16. BE OPTIMAL included a reference arm (adalimumab [ADA] 40 mg Q2W); ADA patients switched to BKZ at Wk52 (ADA/BKZ). BE OPTIMAL Wk52 and BE COMPLETE Wk16 completers could enter BE VITAL (open-label extension; NCT04009499), where all patients received BKZ.
Post-hoc data reported for patients with baseline skin involvement (≥3% body surface area) and nail psoriasis (modified Nail Psoriasis Severity Index >0). Efficacy reported to Wk104 of BE OPTIMAL/Wk100 of BE COMPLETE. Missing data imputed using non‑responder, multiple or worst-category imputation.
Safety data are reported for all patients treated with BKZ.
Results: Of 263/852 (30.9%) bDMARD-naïve and 159/400 (39.8%) TNFi-IR patients with baseline skin and nail psoriasis, 230 (87.5%) and 136 (85.5%) patients completed Wk104/Wk100.
Efficacy responses at Wk52 on BKZ were sustained to Wk104/Wk100 across joint, skin, nail, physical function and composite outcomes. ADA/BKZ cohort showed sustained responses after switch.
For bDMARD-naïve and TNFi-IR patients on BKZ, the exposure-adjusted incidence rates per 100 patient-years (EAIR/100 PY) for ≥1 treatment-emergent adverse event (TEAE) were 154.9 and 78.8, respectively; and for serious TEAEs, 6.6 and 5.2 respectively. None of the reported Candida infections were serious or systemic; all 3 deaths were deemed unrelated to treatment.
Conclusions: BKZ treatment demonstrated sustained clinical efficacy to 2 years in patients with PsA, skin involvement and nail psoriasis, regardless of prior TNFi treatment. BKZ was well tolerated; consistent safety profile to previous reports.1